160 related articles for article (PubMed ID: 29859793)
1. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
[TBL] [Abstract][Full Text] [Related]
3. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D;
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Thind G; Johal B; Follwell M; Kennecke HF
Radiat Oncol; 2014 May; 9():124. PubMed ID: 24885554
[TBL] [Abstract][Full Text] [Related]
5. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
Matzinger O; Roelofsen F; Mineur L; Koswig S; Van Der Steen-Banasik EM; Van Houtte P; Haustermans K; Radosevic-Jelic L; Mueller RP; Maingon P; Collette L; Bosset JF;
Eur J Cancer; 2009 Nov; 45(16):2782-91. PubMed ID: 19643599
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer.
Mineur L; Vazquez L; Belkacemi M; Toullec C; Bentaleb N; Boustany R; Plat F
Curr Oncol; 2023 Sep; 30(9):8563-8574. PubMed ID: 37754536
[TBL] [Abstract][Full Text] [Related]
8. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma.
Li J; Huang C; Wang X; Li Z; Shen Y
Clin Transl Oncol; 2024 Mar; 26(3):739-746. PubMed ID: 37568008
[TBL] [Abstract][Full Text] [Related]
10. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
[TBL] [Abstract][Full Text] [Related]
11. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
12. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
Flam M; John M; Pajak TF; Petrelli N; Myerson R; Doggett S; Quivey J; Rotman M; Kerman H; Coia L; Murray K
J Clin Oncol; 1996 Sep; 14(9):2527-39. PubMed ID: 8823332
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
[TBL] [Abstract][Full Text] [Related]
14. Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma.
Gordeyev SS; Rasulov AO; Gorbounova VA; Tkachev SI; Glebovskaya VV; Fedyanin MY; Besova NS; Surayeva YE
Cancer Chemother Pharmacol; 2017 Sep; 80(3):623-629. PubMed ID: 28766008
[TBL] [Abstract][Full Text] [Related]
15. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
[TBL] [Abstract][Full Text] [Related]
16. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
17. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
18. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
19. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study.
Li J; Xu H; Zou J; Wang X; Li Z; Shen Y
Scand J Gastroenterol; 2021 Apr; 56(4):432-436. PubMed ID: 33556252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]